The early detection of
cancer is considered crucial in developing a truly effective approach to
dealing with the disease. There are, of course, many types of cancers, but
early detection, before symptoms develop, could have a dramatic effect on the
ability of doctors to successfully treat the disease before its spread makes it
untreatable. In conjunction with the need for early detection is the search for
a relatively simple and non-invasive method of detection. Less invasive tests
would make it easier for patients, encouraging them to go in for tests, and it
would also lower costs. With such technologies, it’s possible that cancer
screening could someday become routine across the general population, making
successful outcomes far more likely.
VolitionRx is developing
unique blood-based cancer diagnostic tests. The company’s proprietary
Nucleosomics technology, and associated NuQ assays, can effectively spot and
measure nucleosome structures in the blood, a red flag for the presence of
cancerous cells. Positive results in early tests have led the company to
recently announce the commencement of effectiveness trials on a larger scale.
In collaboration with Hvidovre Hospital in Denmark, samples collected earlier
from 4,800 patients are being put through a blind retrospective study to
further confirm the accuracy of the company’s NuQ assays for the initial
screening of colorectal cancer. The samples assessed in the study are from
patients who have undergone a colonoscopy and have confirmed presence or
absence of colorectal cancer, other malignancies, polyps, or benign bowel
diseases. Early tests displayed 85% detection rates for colorectal cancer and
more than 50% of precancerous polyps.
In addition, the company is
also developing HyperGenomics, designed to detect specific signatures from
cancer biopsies by reading hypersensitive sites along the DNA string. The idea
is to better identify subtypes of the disease, allowing more highly focused
therapies.
For additional information,
visit www.volitionrx.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
